Rhode Island 2025 Regular Session Status: In Committee 10 D cosponsors

HB 5913 — AN ACT RELATING TO HEALTH AND SAFETY -- PRESERVING ACCESS TO AFFORDABLE DRUGS

Last action — 03/11/2025 Committee recommended measure be held for further study

  1. ✓
    Introduced
  2. 2
    In Committee
  3. 3
    Passed House
  4. 4
    Passed Senate
  5. 5
    To Executive
  6. 6
    Enacted

This bill died with 2025 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.

Summary

Provides that an agreement resolving a patent infringement claim, in connection with the sale of a pharmaceutical product, is to be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value.

Bill Text

We don't have the full text on file for this bill yet.

Read HB 5913 on the official Rhode Island source →

Action History

  1. 03/11/2025 Committee recommended measure be held for further study

  2. 03/07/2025 Scheduled for hearing and/or consideration (03/11/2025)

  3. 02/28/2025 Introduced, referred to House Judiciary

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

10 sponsors · 0 co-sponsors · 104 not signed on

Sponsors (10)

Co-sponsors (0)

None.

Not signed on (104)

104 members have not signed on to this bill.

Show all 104 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 5913 do?
Provides that an agreement resolving a patent infringement claim, in connection with the sale of a pharmaceutical product, is to be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value.
Who sponsors HB 5913?
HB 5913 is sponsored by Katherine S. Kazarian (Democratic), Jennifer A. Stewart (Democratic), Karen Alzate (Democratic), Rebecca M. Kislak (Democratic), Jennifer Smith Boylan (Democratic), Earl A. Read, III (Democratic), Matt S. Dawson (Democratic), Michelle E. McGaw (Democratic), Joseph J. Solomon, Jr. (Democratic), and Jenni A. Furtado (Democratic).
What is the current status of HB 5913?
This bill died with 2025 Regular Session. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HB 5913?
Track HB 5913 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 5913

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HB 5913

Last checked for changes 3 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →